Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome



Status:Not yet recruiting
Conditions:Other Indications, Neurology
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:2 - 18
Updated:2/23/2019
Start Date:April 2019
End Date:September 2021
Contact:Medical Information
Email:medinfo@gwpharm.com, medinfo@greenwichbiosciences.com
Phone:+44 (0) 1223 266 800

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing
symptom severity when compared with placebo, in patients with Rett syndrome.


Key Inclusion Criteria:

- Patient (if possessing adequate understanding, in the investigator's opinion) and/or
her parent(s)/legal representative is willing and able to give informed consent/assent
for participation in the trial.

- Patient and her caregiver are willing and able (in the investigator's opinion) to
comply with all trial requirements (including the completion of all caregiver
assessments by the same caregiver throughout the trial).

- Patient must weigh at least 9 kg.

- Clinical diagnosis of Rett syndrome (typical or atypical), defined according to
RettSearch Consortium criteria.

- Confirmed genetic mutation of the MECP2 gene.

- Patient must be post-regression (≥ 6 months since last loss of hand use or verbal
language or gross motor regression).

- All medications or interventions (including antiepileptic drugs [AEDs] and
non-pharmacological interventions - dietary supplements, probiotics, physical therapy,
speech therapy, etc.) for Rett syndrome-related symptoms must have been stable for 4
weeks prior to screening and the patient/caregiver must be willing to maintain a
stable regimen throughout the trial.

- Ability to swallow the investigational medicinal product (IMP) provided as a liquid
solution, or the ability for IMP to be delivered via gastrostomy (G) or nasogastric
(NG) feeding tube (only G-or NG-tubes made from polyurethane or silicon are allowed).

- Patient and/or parent(s)/legal representative is willing to allow the responsible
authorities to be notified of participation in the trial, if mandated by local law.

- Patient and/or parent(s)/legal representative is willing to allow the patient's
primary care practitioner (if she has one) and consultant (if she has one) to be
notified of participation in the trial, if the primary care practitioner/consultant is
different to the investigator.

Key Exclusion Criteria:

- Patient meets exclusion criteria for Rett syndrome diagnosis (traumatic brain injury,
neurometabolic disease, or severe infection that causes neurological problems; grossly
abnormal psychomotor development in the first 6 months of life).

- Patient has clinically significant abnormal laboratory values, in the investigator's
opinion.

- Patient is taking more than 2 concurrent AEDs.

- Any history of suicidal behavior or any suicidal ideation in the last month or at
screening.

- Clinically relevant abnormalities in the ECG measured at screening or randomization.

- Concurrent cardiovascular conditions which will, in the investigator's opinion,
interfere with the ability to assess her ECGs or put the patient at risk because of
participation in the trial.

- First or second degree relative with a history of significant ECG abnormalities, in
the opinion of the investigator (e.g. cardiac arrest, sudden death).

- Any known or suspected hypersensitivity to cannabinoids or any of the excipients of
the IMP (active or placebo), such as sesame oil.

- Patient has significantly impaired hepatic function at screening, defined as alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × upper limit of normal
(ULN) or total bilirubin > 2 × ULN.

- Pregnant (positive pregnancy test) or lactating.

- Received an IMP within the 3 months prior to screening.

- Patient has been taking felbamate for less than 1 year prior to screening.

- Currently using or has used recreational or medicinal cannabis, cannabinoid-based
medications (including Sativex®), or cannabidiol oral solutions (including CBD-OS
[GWP42003-P]) within the 3 months prior to screening and is unwilling to abstain for
the duration of the trial.

- Patient has a positive delta-9-tetrahydrocannabinol (THC) test at screening.

- Any other systemic dysfunction (e.g., gastrointestinal, renal, respiratory) or
significant disease or disorder which, in the opinion of the investigator, may either
put the patient at risk because of participation in the trial, may influence the
result of the trial, or the patient's ability to participate in the trial.

- Any abnormalities identified following a physical examination of the patient that, in
the opinion of the investigator, would jeopardize the safety of the patient if she
took part in the trial.

- Patient has been previously randomized into this trial.

- Patient has travel outside the country of residence planned during the trial.
We found this trial at
15
sites
Greenwood, South Carolina 29646
?
mi
from
Greenwood, SC
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Liverpool,
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Paul, Minnesota 55101
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials